Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dow Corning

This article was originally published in The Gray Sheet

Executive Summary

Completes leadership transition with appointment of President and CEO Richard Hazelton, 51, as chairman of the board "effective immediately." Hazelton replaces Keith McKennon, 60, who has served as chairman since February 1992 and is retiring. Hazelton will continue as CEO, a position he took over from McKennon in June 1993, but will relinquish the position of company president, which he has held since January 1993. Executive Vice President Gary Anderson, 49, becomes Dow Corning president. McKennon, a crisis management specialist, came to Dow Corning from Dow Chemical in February 1992, at the height of the silicone breast implant controversy ("The Gray Sheet" Feb. 17, 1992, p. 5)

You may also be interested in...



GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health

Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.

CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings

FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.

Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds

New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT002812

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel